Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Receivables (2021 - 2025)

Historic Receivables for BridgeBio Pharma (BBIO) over the last 4 years, with Q3 2025 value amounting to $116.5 million.

  • BridgeBio Pharma's Receivables changed N/A to $116.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.5 million, marking a year-over-year change of. This contributed to the annual value of $4.7 million for FY2024, which is 10085.07% up from last year.
  • BridgeBio Pharma's Receivables amounted to $116.5 million in Q3 2025.
  • BridgeBio Pharma's Receivables' 5-year high stood at $116.5 million during Q3 2025, with a 5-year trough of $2.4 million in Q4 2023.
  • Its 4-year average for Receivables is $54.3 million, with a median of $43.5 million in 2021.
  • Within the past 5 years, the most significant YoY rise in BridgeBio Pharma's Receivables was 10085.07% (2024), while the steepest drop was 10085.07% (2024).
  • Over the past 4 years, BridgeBio Pharma's Receivables (Quarter) stood at $10.2 million in 2021, then crashed by 76.89% to $2.4 million in 2023, then skyrocketed by 100.85% to $4.7 million in 2024, then skyrocketed by 2367.56% to $116.5 million in 2025.
  • Its Receivables was $116.5 million in Q3 2025, compared to $76.9 million in Q2 2025 and $115.3 million in Q1 2025.